A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease

Launched by BEYONDBIO INC. · Mar 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called BEY2153 to see if it is safe and effective for people with early Alzheimer's disease. The trial will involve adults aged 55 to 85 who have been diagnosed with mild cognitive impairment or mild Alzheimer's disease. To participate, individuals will need to meet specific health criteria, including having certain levels of cognitive function and a positive result on an imaging test for amyloid, a protein often associated with Alzheimer's.

Participants in the trial will take BEY2153 by mouth once a day for a period of 26 weeks. They will be randomly assigned to one of three groups: two groups will receive either the medication or a placebo (a non-active treatment), while the third group will continue in an open-label extension study for an additional 26 weeks. Throughout the study, participants will be monitored closely for any side effects or changes in their condition. This trial is not yet recruiting, so interested individuals will need to wait for it to start before applying.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female adults at the age of ≥ 55 to ≤ 85 at the time of informed consent
• • Patients diagnosed according to the NIA-AA 2024 Criteria for Diagnosis with Mild Cognitive Impairment (MCI) or diagnosed with mild Alzheimer's disease
• • CDR-GS 0.5-1.0 at Screening
• • MMSE ≥ 20 at Screening
• • Amyloid-positive at amyloid PET scan
• • Patients who are capable of understanding information provided and can voluntarily sign written informed consent form
• Exclusion Criteria:
• • Subjects diagnosed with cognitive impairment due to causes other than substrate causes such as brain lesions, psychiatric disorders, or Alzheimer's disease (e.g., stroke, Parkinson's disease, Lewy body disease, vascular dementia)
• • Subjects with any of the following cardiovascular diseases at Screening
• • \* Cerebrovascular disease within the past 6 months (cerebral infarction, cerebral hemorrhage, transient ischemic attack, etc.)
• • Myocardial infarction or unstable angina pectoris within the past 6 months
• • New York Heart Association (NYHA) Class II congestive heart failure
• • QTcF ≥450 msec or clinically significant electrocardiogram (ECG) abnormalities
• • Patients with malignant tumors
• • Patients with medical conditions that can affect cognitive decline such as hypothyroidism, vitamin B12 or folate deficiency, niacin deficiency, etc.
• • Patients with a history of alcohol related disorders within the past 6 months
• • Patients with a positive HIV antibody test result at Screening
• • Patients with a positive HBs antigen or HCV antibody test at Screening
• • Patients with active bacterial infections who have received antibiotics within 7 days prior to Screening.
• • Patients with a history of hypersensitivities to any of the components of investigational product
• • Patients who have been hospitalized or treated for suicidal behavior within 5 years prior to Screening or whose C-SSRS results at Screening indicate serious suicidal ideation or behavior
• • Patients who have received treatment for Alzheimer's disease (e.g., Lecanemab) within 6 months prior to Screening
• • Patients expected to require the administration of a long-acting benzodiazepine (BDZ) for the treatment of sleep disorders at Screening
• * Any of the following laboratory test values at Screening:
• • Serum Creatinine \>1.5×ULN or eGFR (MDRD) \<40 mL/min/1.73 m2
• • Any of the following: AST, ALT \>3×ULN, or Total bilirubin \>2xULN
• • Women who test positive for pregnancy at Screening, or women and men of childbearing potential who are planning to become pregnant, or who do not agree to use adequate contraception\* during the study and for 4 weeks after the end of study drug administration
• • \*Adequate contraception: complete abstinence, hormonal contraceptives with no known drug interactions \[Levonorgestrel intrauterine system (IUS) (Mirena), Medroxyprogesterone\], surgical sterilization (including vasectomy, bilateral salpingectomy and ligation). However, intermittent abstinence (e.g., using ovulation timing, symptothermal method, or post-ovulation) or external ejaculation are not considered adequate contraception.
• • Pregnant or lactating women or women who are tested positive for pregnancy at Screening
• • Patients treated with other IP within 4 weeks prior to screening
• • Patients who are considered ineligible for study participation for other reasons based on the judgment of the investigator
• • \[Extension Study\]
• Inclusion Criteria:
• • Patients who completed the 26-week visit in the Main Study
• • Patients who provided written consent to participate in the Extension Study
• Exclusion Criteria:
• • Subjects who have dropped out of the Main Study
• • Patients who, in the investigator's judgement, are not suitable for participation in Extension Study
• * Any of the following laboratory test values at Baseline:
• • Serum Creatinine \>1.5×ULN or eGFR (MDRD) \<40 mL/min/1.73 m2
• • Any of the following: AST, ALT \>3×ULN, or Total bilirubin \>2xULN